Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy
Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy have?
Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy has 125 citations in the OpenAlex counts ScholarIQ stores.
When was Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy published?
Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy has 2010 year in the ScholarIQ index.
What is the open-access status of Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy?
Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy has bronze oa status in the ScholarIQ index.
What is the DOI of Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy?
The DOI for Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy is on the source record.
What is the PMID of Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy?
The PMID for Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy is on the source record.
What is the OpenAlex record for Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy?
The OpenAlex for Cardiac Resynchronization Therapy May Benefit Patients with Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy is on the source record.